Auxiliary oligonucleotides used to improve the efficiency of nucleic acid amplification and detection / quantification.
By using non-extension auxiliary oligonucleotide primers in PCR reactions, the Gibbs free energy of the target nucleic acid secondary structure is reduced, solving the problem of low efficiency in nucleic acid amplification and detection in existing technologies, and achieving efficient and sensitive detection and quantification of target nucleic acids.
Patent Information
- Application Number
- CN201780048426.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2016-08-02
- Filing Date
- 2017-07-26
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2037-07-26
AI Technical Summary
Existing nucleic acid amplification and detection methods are inefficient and make it difficult to achieve efficient detection and quantification of target nucleic acids, especially at low copy numbers.
Non-extension auxiliary oligonucleotides are used as primers in PCR reactions to reduce the Gibbs free energy of the secondary structure of the target nucleic acid, promote the binding of primers to the target nucleic acid, and improve amplification efficiency and sensitivity.
It improves the efficiency and sensitivity of PCR reactions, enabling successful amplification of target nucleic acids at low copy numbers, thus achieving more accurate and sensitive detection and quantification.
Smart Images

Figure CN109642253B_ABST
Abstract
Description
Invention Field
[0001] This invention relates to the field of in vitro diagnostics. Within this field, the invention relates to improved methods for detecting target nucleic acids that may be present in samples (e.g., biological or non-biological samples). Specifically, the invention relates to the detection and quantification of target nucleic acids with the assistance or aid of non-extension helper oligonucleotides that enhance primer activity. By enhancing primer activity, non-extension helper oligonucleotides improve amplification efficiency, resulting in larger and enhanced amplicon production. Therefore, this improvement enables more efficient and sensitive detection and quantification methods. The invention further provides reaction mixtures and kits containing non-extension helper oligonucleotides, primers, and probes for the detection and quantification of target nucleic acids that may be present in samples. This invention is useful, for example, for the detection and quantification of viral or bacterial nucleic acids in samples. Background of the Invention In the field of molecular diagnostics, nucleic acid amplification and detection / quantification are of significant importance. An example of diagnostic applications of nucleic acid amplification and detection is the detection and amplification of microbial nucleic acids. Such microbial nucleic acids can include bacterial nucleic acids and / or viral nucleic acids. The amplification and detection / quantification techniques are suitable for routine blood donation screening for viral nucleic acid targets, such as human papillomavirus (HPV) or West Nile virus (WNV), or for the presence of human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), or hepatitis C virus (HCV). These amplification and detection / quantification techniques are also suitable for the analysis of bacterial nucleic acid targets or oncology markers.
[0003] The most advanced and widely used method for amplifying (and detecting / quantifying) nucleic acid targets is polymerase chain reaction (PCR). Other amplification techniques include ligase chain reaction, polymerase ligase chain reaction, Gap-LCR, repair chain reaction, 3SR, NASBA, strand displacement amplification (SDA), transcription-mediated amplification (TMA), and Qβ-amplification.
[0004] Automated systems for PCR-based analysis often utilize real-time detection of product amplification during the PCR process within the same reaction vessel. A key aspect of such methods is the use of modified oligonucleotides carrying reporter groups or labels. PCR utilizes polymerases (US Patent Nos. 4,683,195 and 4,683,202). A significant improvement is, for example, the real-time detection of amplified products during PCR using modified oligonucleotides carrying reporter groups or labels known as hydrolytic or 5'-nuclease probes, such as those used in commercial assays on COBAS®TaqMan® (US Patent Nos. 5,210,015 and 5,487,972). Other improved amplification and detection methods are known as molecular beacon technology (International Patent Publication No. WO 95 / 13399) or methods utilizing oligonucleotides containing a minor groove binding (MGB) moiety (International Patent Publications Nos. WO 03 / 062445 and WO 2006 / 135765). It is further known that the application of primers containing added oligonucleotides (with high GC content at the 5' end of at least one of these primers) has shown improved amplification efficiency (Liu, people, Genome Research 7:389-398 (1997); International Patent Publication No. WO 01 / 94638; and US Patent Publication No. US 2004 / 0110182). After approximately 12–40 PCR cycles, the final amount of amplified product was significantly higher for primers, for example, those with a GGAC unit added to the 5' end, than for unmodified primers.
[0005] Afonina, people, BioTechniques 43(3):1-3 (2007); International Patent Publication No. WO 2006 / 135765 describes an increase in real-time PCR fluorescence signal, and thereby improved amplification efficiency by using primers with short, adenine and thymine-rich wings randomly dispersed at the 5' end and minor groove binding agent (MGB) fluorescent hybridization probes.
[0006] Similarly, Babiel et al. (US Patent Publication No. US 2014 / 0113279) described how the addition of poly-N primers can lead to a reduction or inhibition of the formation of unwanted high molecular weight products, thereby avoiding false negative or false positive results.
[0007] Therefore, there is always a need in the art to improve existing methods. For example, there is a need in the art to provide a method for the simple and reliable detection and quantification of nucleic acid targets. In particular, there is a need to improve the efficiency of DNA amplification and detection / quantification. Invention Overview Some embodiments of the present invention relate to novel methods and uses for amplifying, detecting, and quantifying target nucleic acids in samples (e.g., biological or non-biological samples). For example, some embodiments of the present invention relate to single-channel or multi-channel detection and quantification of microorganisms such as viruses (e.g., HPV, WNV, HAV, HBV, HCV, and HIV) via real-time polymerase chain reaction (PCR) in a single test tube or reaction vessel. The improvements are based on the application of non-extension auxiliary oligonucleotides in amplification reactions such as PCR. It is believed that the non-extension auxiliary oligonucleotides act as an auxiliary oligonucleotide or auxiliary primer because they promote and enhance amplification mediated by (extension) primers. It is also believed that the presence of the non-extension auxiliary oligonucleotides reduces or lowers the Gibbs free energy of the secondary structure of the target region of the target nucleic acid. In some cases, it is believed that the non-extension auxiliary oligonucleotides reduce / lower the Gibbs free energy of the secondary structure of the primer-binding region of the target nucleic acid. The non-extension auxiliary oligonucleotides can anneal in one or more of the same regions as the primers. However, unlike the primers, the non-extension auxiliary oligonucleotides do not extend. In other words, the non-extension auxiliary oligonucleotide does not extend to generate an amplicon. Instead of extension, the non-extension auxiliary oligonucleotide promotes and enhances the target reachability of the one or more extended primers that generate an amplicon. That is, like the extension primer, the non-extension auxiliary oligonucleotide anneals with the target nucleic acid, but unlike the extension primer, the non-extension auxiliary oligonucleotide does not extend. There are many ways to prevent oligonucleotide extension, which are or will be well known to those skilled in the art. For example, the addition of a polyadenylate sequence to the 3' end of the oligonucleotide prevents extension. It is also believed that the polyadenylate sequence cannot anneal with any part of the target nucleic acid, thereby destabilizing the interaction between the non-extension auxiliary oligonucleotide and the target nucleic acid, which in turn opens the secondary structure and allows the (extension) primer to substitute the non-extension auxiliary oligonucleotide. In addition, replacing the 3'-OH group with a phosphate ester group (i.e., phosphorylation) also prevents extension. It is believed that the non-extension auxiliary oligonucleotide assists amplification by reducing the Gibbs free energy of the secondary structure in the primer-binding region of the target nucleic acid, thereby increasing the reachability of the extended one or more primers. See also, Figure 2 and 4 This leads to improved PCR amplification, resulting in the accumulation of more PCR products (i.e., amplicons) in the presence of the non-extension assist oligonucleotide compared to the absence of the non-extension assist oligonucleotide. See also, Figure 1 and 3In other words, the non-extension assist oligonucleotide improves and / or enhances the overall efficiency of PCR assays. Because the efficiency of PCR assays is improved, even small amounts of starting material (i.e., low copy numbers) may be successfully amplified in the presence of the non-extension assist oligonucleotide. Therefore, the non-extension assist oligonucleotide also increases the sensitivity of the assay.
[0009] The implementation scheme includes methods for detecting and quantifying target nucleic acids, including performing at least one cyclic step, which may include an amplification step and a hybridization step. Furthermore, the implementation scheme includes primers, probes, and one or more non-extension helper oligonucleotides, as well as a kit designed for detecting and quantifying target nucleic acids in a single reaction vessel or test tube.
[0010] This invention also provides methods for detecting the presence or absence of target nucleic acids in biological samples from individuals. These methods can be used to detect the presence or absence of target nucleic acids in plasma for blood screening and diagnostic testing. Additionally, those skilled in the art can use the same tests to evaluate urine and other sample types for the detection and / or quantification of target nucleic acids. Such methods typically involve performing at least one cyclic step, which includes an amplification step and a dye-binding step. Typically, the amplification step involves contacting the sample with multiple oligonucleotide primer pairs and, in this case, one or more non-elongating auxiliary oligonucleotides to produce one or more amplification products (if the nucleic acid molecule is present in the sample), and the dye-binding step involves contacting the amplification product with a double-stranded DNA-binding dye. Such methods also include detecting the presence or absence of binding of the double-stranded DNA-binding dye in the amplification product, wherein the presence of binding indicates the presence of the target nucleic acid in the sample, and wherein the absence of binding indicates the absence of the target nucleic acid in the sample. A representative double-stranded DNA-binding dye is ethidium bromide. Other nucleic acid-binding dyes include DAPI, Hoechst dyes, PicoGreen®, RiboGreen®, OliGreen®, and cyanine dyes such as YO-YO® and SYBR® Green. Alternatively, such a method may also include determining the melting temperature between the amplification product and the double-stranded DNA binding dye, wherein the melting temperature confirms the presence or absence of nucleic acid.
[0011] In another embodiment, a kit is provided for detecting and / or quantifying one or more target nucleic acids. The kit may include a set of one or more primers specific for the amplification of the target nucleic acid; one or more non-extension helper oligonucleotides; and one or more detectable oligonucleotide probes specific for the detection of the amplification product.
[0012] In one aspect, the kit may include a probe already labeled with a donor and a corresponding acceptor moiety (e.g., another fluorescent moiety or dark quencher), or may include a fluorophore moiety for labeling the probe. The kit may also include nucleoside triphosphates, a nucleic acid polymerase, and buffers necessary for the function of the nucleic acid polymerase. The kit may also include a package insert and instructions regarding the use of the primers, non-extension helper oligonucleotides, probes, and the fluorophore moiety to detect the presence or absence of the amplification product / target nucleic acid in a sample.
[0013] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While similar or equivalent methods and materials to those described herein may be used to practice or test the subject matter of this invention, suitable methods and materials are described below.
[0014] Details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will become apparent from the drawings, the detailed description, and the claims. Brief description of the attached diagram Figure 1 The experiment's real-time PCR growth curves are shown, which display the primers, probes, and non-extension helper oligonucleotides, as well as probes specific to the target nucleic acid (the target nucleic acid of HCV).
[0016] Figure 2 The predicted secondary structure of the target region in the presence of non-elongation auxiliary oligonucleotides (HCV) is shown, with a ΔG of -107.2 kcal / mol.
[0017] Figure 3 The experiment's real-time PCR growth curves are shown, which display the primers, probes, and non-extension helper oligonucleotides, as well as probes specific to the target nucleic acid (the target nucleic acid of HCV).
[0018] Figure 4 The predicted secondary structure of the target region in the presence of non-elongation auxiliary oligonucleotides (HCV) is shown, with a ΔG of -98.6 kcal / mol. Invention Details This invention relates to novel and improved methods and uses for amplifying, detecting, and quantifying nucleic acid targets that may be present in samples (e.g., biological samples), comprising at least primer pairs for generating amplicons, detectable probes specific to said amplicons, and non-extension helper oligonucleotides. The improvements are specifically based on the fact that the presence of non-extension helper oligonucleotides enhances and increases amplification (i.e., amplicon generation). That is, said non-extension helper oligonucleotides enhance and improve the activity and efficiency of one or more primers for their extension, thereby improving and increasing the efficiency of the PCR reaction. This has the effect of increasing the sensitivity of the assay. This invention can be used for any number of applications, including, but not limited to, the amplification and detection / quantification of microbial nucleic acids (e.g., viral or bacterial nucleic acids). Examples of viruses used in conjunction with this invention include HPV, WNV, HAV, HBV, HCV, and HIV.
[0020] The diagnosis of microbial (e.g., viral or bacterial) infections via nucleic acid amplification provides a method for the rapid, accurate, reliable, specific, and sensitive detection and / or quantification of infection. This article describes a real-time reverse transcriptase PCR assay for the detection and / or quantification of microbial nucleic acids in non-biological or biological samples. Primers and probes for the detection and / or quantification of target nucleic acids (such as microbial nucleic acids, like viral or bacterial nucleic acids) are provided, as well as articles or kits containing such primers and probes. The increased specificity and sensitivity of real-time PCR for the detection of target nucleic acids compared to other methods, along with the improved features of real-time PCR (including sample congestion and real-time detection and quantification of amplified products), make this technology feasible for routine diagnosis of microbial infections (e.g., viral or bacterial infections) in clinical laboratories. Additionally, this technology can be used for blood screening and for prognosis. Such an assay can also be multiplexed in parallel with other assays for the detection of other target nucleic acids (e.g., other microbial nucleic acids, or other / different genotypes of the same microorganism).
[0021] As an example, the present invention includes oligonucleotide primers, non-elongation helper oligonucleotides, and fluorescently labeled hydrolysis probes that hybridize with the HCV genome to specifically identify HCV using, for example, TaqMan® detection technology.
[0022] The terms “primer” or “extension primer” as used herein are known to those skilled in the art and refer to oligomeric compounds, primarily oligonucleotides, but also to modified oligonucleotides capable of “initiating” DNA synthesis by template-dependent DNA polymerases, i.e., oligonucleotides having a free 3'-OH group at their 3' end, wherein additional “nucleotides” can be linked by template-dependent DNA polymerases to form 3' to 5' phosphodiester bonds, wherein deoxyribonucleotide triphosphates are used and wherein pyrophosphate is released.
[0023] Specifically, the disclosed method may include performing at least one cyclic step comprising amplifying one or more portions of a nucleic acid molecular gene target from a sample using one or more primer pairs. As used herein, “primer” or “extension primer” refers to an oligonucleotide primer that specifically anneals to a nucleic acid sequence present in the target region of the sample and initiates DNA synthesis from it under appropriate conditions, thereby producing various amplification products. The amplification products should contain a nucleic acid sequence complementary to one or more detectable probes specific to the target nucleic acid. As used herein, “probe” or “detectable probe” refers to an oligonucleotide probe that specifically anneals to a nucleic acid sequence present in the target region of the sample. Each cyclic step includes an amplification step, a hybridization step, and a detection step, wherein the sample is contacted with one or more detectable probes used to detect the presence or absence of the target nucleic acid in the target region of the sample.
[0024] As used herein, the term "amplification" refers to the process of synthesizing a nucleic acid molecule that is complementary to one or both strands of a template nucleic acid molecule (e.g., a nucleic acid molecule derived from a microorganism such as a virus or bacteria). Amplification of nucleic acid molecules typically involves denaturing the template nucleic acid, annealing the primers to the template nucleic acid at a temperature below the primer's melting temperature, and enzymatically extending the primers to produce an amplification product. Amplification typically requires deoxyribonucleoside triphosphates, DNA polymerase (e.g., Platinum® Taq), and appropriate buffers and / or the presence of cofactors (e.g., MgCl2 and / or KCl) necessary for optimal polymerase activity.
[0025] The term "hybridization" refers to the annealing of one or more probes with the amplification product. Hybridization conditions typically include temperatures below the probe's melting temperature, but avoiding non-specific hybridization of the probe.
[0026] The term "5' to 3' nuclease activity" refers to the activity of a nucleic acid polymerase, which is usually associated with the synthesis of nucleic acid chains, in which nucleotides are removed from the 5' end of the nucleic acid chain.
[0027] The term "thermostable polymerase" refers to a thermostable polymerase that catalyzes the formation of primer extension products complementary to the template and does not undergo irreversible denaturation when subjected to elevated temperatures for the duration required to denature the double-stranded template nucleic acid. Typically, synthesis begins at the 3' end of each primer and proceeds along the template strand in the 5' to 3' direction. Thermostable polymerases have been isolated from *Thermophyton flavus* (…). Thermus flavus ), Rhodophyton floccosum ( T. ruber ), thermophilic bacteria ( T. thermophilus ), aquatic thermophilic bacteria ( T. aquaticus ), Milkweed fever ( T. lacteus ), Red-living thermophilus ( T. rubens), thermophilic steatobacterium ( Bacillus stearothermophilus ) and thermophilic methanogens ( Methanothermus fervidus Nevertheless, non-thermally stable polymerases can also be used in PCR assays, provided that the enzyme is supplemented as needed.
[0028] The term "complement of a nucleic acid" refers to a nucleic acid that has the same length as a given nucleic acid and is exactly complementary to it.
[0029] The terms “extension” or “stretching” are used when referring to nucleic acids, in which additional nucleotides (or other similar molecules) are incorporated into the nucleic acid. For example, nucleic acids may be extended using a nucleotide-incorporated biocatalyst, such as a polymerase that typically adds nucleotides to the 3' end of a nucleic acid.
[0030] In the context of two or more nucleic acid sequences, the term "identical" or percentage "identity" indicates that two or more sequences or subsequences are identical or that a specified percentage of nucleotides are the same when for maximum correspondence and alignment, for example, as used by one of the sequence alignment algorithms available to a technician or as measured by visual inspection. An exemplary algorithm suitable for determining the percentage of sequence identity and sequence similarity is the BLAST program, described in, for example, Altschul et al. (1990), "Basic local alignment search tool." J. Mol. Biol. 215:403-410, Gish et al. (1993) "Identification of protein coding regions by database similarity search", Nature Genet. 3:266-272, Madden et al. (1996) "Applications of network BLAST server", Meth. Enzymol. 266:131-141, Altschul et al. (1997) "GappedBLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402, and Zhang et al. (1997) "PowerBLAST: A new networkBLAST application for interactive or automated sequence analysis andannotation", Genome Res. 7:649-656.
[0031] In the context of oligonucleotides, "modified nucleotide" refers to a change in which at least one nucleotide of an oligonucleotide sequence is replaced by a different nucleotide that gives the oligonucleotide the desired properties. Exemplary nucleotide modifications that can be substituted in the oligonucleotides described herein include, for example, tert-butylbenzyl, phosphate esters, C5-methyl-dC, C5-ethyl-dC, C5-methyl-dU, C5-ethyl-dU, 2,6-diaminopurine, C5-propynyl-dC, C5-propynyl-dU, C7-propynyl-dA, C7-propynyl-dG, C5-propynylamino-dC, C5-propynylamino-dU, C7-propynylamino-dA, C7-propynylamino-dG, 7-deazo-2-deoxyxanthoside, pyrazolopyrimidine analogs, pseudo-dU, nitropyrrole, nitroindole, 2'-O-methylribo-U, 2'-O-methylribo-C, N4-ethyl-dC, N6-methyl-dA, 5-propynyl-dU, 5-propynyl-dC, etc. Many other modified nucleotides that can be substituted into oligonucleotides are mentioned herein or otherwise known in the art. In some embodiments, the modified nucleotide substitution alters the melting temperature (Tm) of the oligonucleotide relative to the melting temperature of the corresponding unmodified oligonucleotide. For further illustration, in some embodiments, certain modified nucleotide substitutions can reduce nonspecific nucleic acid amplification (e.g., minimize primer dimer formation, etc.), increase the yield of the intended target amplicon, and / or so on. Examples of these types of nucleic acid modifications are described, for example, in U.S. Patent No. 6,001,611. Other modified nucleotide substitutions may alter the stability of the oligonucleotide or provide other desirable characteristics.
[0032] Detection of target nucleic acids This invention provides a method for detecting and quantifying target nucleic acids in a sample by amplifying a portion of the target nucleic acid sequence. As an example, a method for detecting and quantifying HCV in a sample by amplifying a portion of the HCV nucleic acid sequence is provided. Specifically, embodiments of this invention provide primers, non-extension helper oligonucleotides, and probes for amplifying and detecting / quantifying HCV nucleic acid molecular targets.
[0033] Primers, non-extension helper oligonucleotides, and probes are provided for the amplification, detection, and quantification of HCV. HCV nucleic acids other than those exemplified herein can also be used to detect HCV in a sample. For example, those skilled in the art can evaluate functional variants for specificity and / or sensitivity using conventional methods. Representative functional variants may include, for example, one or more deletions, insertions, and / or substitutions in the HCV nucleic acids disclosed herein.
[0034] More specifically, each of the oligonucleotide embodiments comprises a nucleic acid having a sequence selected from SEQ ID NO:1-5, a substantially equivalent variant thereof, wherein said variant has at least, for example, 80%, 90%, or 95% sequence identity with one of SEQ ID NO:1-5, or a complement of SEQ ID NO:1-5 and its variants. The forward primer, reverse primer, and detectable probe (SEQ ID NO:1-4) are derived from a commercially available HCV genotyping assay (cobas® HCV GT, for use with Roche's cobas® 4800 system).
[0035] Table 1: HCV oligonucleotides
[0036] In one embodiment, the set of HCV primers, non-extension helper oligonucleotides, and probes described above is used to provide detection of HCV in biological samples suspected of containing HCV (Table 1). The set of primers, non-extension helper oligonucleotides, and probes may comprise or consist of primers, non-extension helper oligonucleotides, and probes specific to HCV nucleic acid sequences, which comprise or consist of nucleic acid sequences of SEQ ID NO: 1-5. In another embodiment, the primers, non-extension helper oligonucleotides, and probes targeting HCV comprise or consist of functionally active variants of any one of the primers, non-extension helper oligonucleotides, and probes of SEQ ID NO: 1-5.
[0037] Using the primers, non-extension assist oligonucleotides, and / or probes disclosed in the methods, functionally active variants of any one of the primers, non-extension assist oligonucleotides, and / or probes in SEQ ID NO:1-5 can be identified. A functionally active variant of any one of the primers, non-extension assist oligonucleotides, and / or probes in SEQ ID NO:1-5 refers to a primer, non-extension assist oligonucleotide, and / or probe that provides similar or higher specificity and sensitivity in the method or kit compared to the respective sequences of SEQ ID NO:1-5.
[0038] The variants can be derived from the sequences of SEQ ID NO:1-5, for example, by the addition, deletion, or substitution of one or more nucleotides (such as the addition, deletion, or substitution of one or more nucleotides at the 5' end and / or 3' end of the respective sequences of SEQ ID NO:1-5). As detailed above, primers, non-extension auxiliary oligonucleotides, and / or probes can be chemically modified, i.e., primers, non-extension auxiliary oligonucleotides, and / or probes can contain modified nucleotides or non-nucleotide compounds. Primers, non-extension auxiliary oligonucleotides, and / or probes are modified oligonucleotides. A “modified nucleotide” (or “nucleotide analog”) differs from a natural “nucleotide” in that it is modified, but still consists of a base or a base-like compound, a furanyl pentose sugar or a furanyl pentose sugar-like compound, a phosphate moiety or a phosphate ester-like moiety, or a combination thereof. For example, a “tag” can be attached to the base moiety of a “nucleotide”, thereby obtaining a “modified nucleotide.” The natural base in a “nucleotide” can also be replaced, for example, with 7-deazapurine, thereby also obtaining a “modified nucleotide.” The terms “modified nucleotide” or “nucleotide analog” are used interchangeably in this application. A “modified nucleoside” (or “nucleoside analog”) differs from a natural nucleoside in that it is modified in a manner as outlined above for “modified nucleotide” (or “nucleotide analog”).
[0039] Oligonucleotides include modified oligonucleotides and oligonucleotide analogs that amplify nucleic acid molecules corresponding to target regions. Using computer programs such as OLIGO (Molecular Biology Insights Inc., Cascade, Colo.), oligonucleotides corresponding to, for example, alternative portions of the target can be designed. Important characteristics when designing oligonucleotides to be used as amplification primers include, but are not limited to: an amplification product of appropriate size to facilitate detection (e.g., by electrophoresis), similar melting temperatures for members of a primer pair, and the length of each primer (i.e., primers need to be long enough to anneal and initiate synthesis with sequence specificity, but not so long as to reduce fidelity during oligonucleotide synthesis). Typically, oligonucleotide primers are 8–50 nucleotides in length (e.g., 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or 50 nucleotides).
[0040] The oligonucleotides of the present invention include "helper oligonucleotides" or "non-elongation helper oligonucleotides". In some cases, the non-elongation helper oligonucleotide will partially anneal with a portion of the target nucleic acid. Because the non-elongation helper oligonucleotide is believed to promote the approach of the extension primer or primer to the target nucleic acid, the non-elongation helper oligonucleotide can act on the same or near the place where the extension primer will anneal. Therefore, in some cases, the region of the target nucleic acid in which the non-elongation helper oligonucleotide will partially or completely anneal is the same as that of the extension primer. That is, in some cases, the non-elongation helper oligonucleotide and the extension primer will partially or completely anneal with the same portion of the target nucleic acid. Thus, in some cases, the non-elongation helper oligonucleotide and the extension primer can share partially or completely identical sequences. It is believed that the non-elongation helper oligonucleotide lowers the Gibbs free energy of the secondary structure of the target nucleic acid. This then promotes the annealing of one or more extension primers with the target, which then initiates extension (i.e., nucleic acid synthesis) by DNA polymerase. Thus, the non-elongation helper oligonucleotide To prevent the extension of the auxiliary oligonucleotide itself, any number of modifications can be made to the auxiliary oligonucleotide. Such modifications are well known to those skilled in the art. Examples of such modifications include adding a polyadenylated nucleotide to the 3'-end of the auxiliary oligonucleotide and / or replacing the 3'-OH group with a phosphate ester group (i.e., phosphorylation). It is believed that the addition of a polyadenylated sequence (which is unlikely to anneal with the target nucleic acid) destabilizes the interaction between the non-extending auxiliary oligonucleotide and the target nucleic acid, thereby opening up secondary structures that facilitate the approach of the target nucleic acid region to the (extending) primer.
[0041] In addition to a set of primers, the method may use one or more probes to detect the presence or absence of a target nucleic acid. The term "probe" refers to a synthetically or biologically produced nucleic acid (DNA or RNA) that is designed or selected to contain a specific nucleotide sequence that allows it to specifically (i.e., preferentially) hybridize with a "target nucleic acid" under defined predetermined strictness. A "probe" may be called a "detection probe," meaning it detects the target nucleic acid.
[0042] In some embodiments, the probe may be labeled with at least one fluorescent label. In one embodiment, the probe may be labeled with a donor fluorescent portion (e.g., a fluorescent dye) and a corresponding acceptor portion (e.g., a quencher). In one embodiment, the probe comprises or consists of a fluorescent portion and a nucleic acid sequence comprising or consisting of SEQ ID NO:4.
[0043] Oligonucleotides designed for use as probes can be designed in a similar manner to primers. Implementations can use single probes or probe pairs for detecting amplification products. Depending on the implementation, probe application may include at least one label and / or at least one quencher moiety. Like primers, probes often have similar melting temperatures, and each probe must be long enough to cause sequence-specific hybridization, but not so long as to reduce fidelity during synthesis. Oligonucleotide probes are typically 15–40 nucleotides in length (e.g., 16, 18, 20, 21, 22, 23, 24, or 25).
[0044] The construct may include vectors, each containing one of a primer, a non-extension helper oligonucleotide, and a probe nucleic acid molecule. For example, the construct may include vectors, each containing one of a microbial target primer, a non-extension helper oligonucleotide, and a probe nucleic acid molecule (e.g., for HCV, SEQ ID NO: 1, 2, 3, 4, and 5). The construct may be used, for example, as a control template nucleic acid molecule. Suitable vectors are commercially available and / or produced using conventional recombinant nucleic acid techniques in the art. Nucleic acid molecules may be obtained, for example, through chemical synthesis, direct cloning from a target region, or nucleic acid amplification.
[0045] Constructs suitable for use in the methods typically include sequences encoding selectable markers (e.g., antibiotic resistance genes) for selecting desired constructs and / or transformants, and an origin of replication. The choice of vector system often depends on several factors, including, but not limited to, host cell selection, replication efficiency, selectivity, inducibility, and ease of recovery.
[0046] Constructs containing the target nucleic acid molecule can be propagated within host cells. The term "host cell" as used herein is intended to include both prokaryotic and eukaryotic cells such as yeast, plant, and animal cells. Prokaryotic hosts may include *Escherichia coli* (…). E. coli Salmonella typhimurium ( Salmonella typhimurium Serratia marcescens ( ), Serratia marcescens ) and Bacillus subtilis ( Bacillus subtilis Eukaryotic hosts include yeasts such as Saccharomyces cerevisiae (Saccharomyces cerevisiae). S. cerevisiae ), fission yeast ( S. pombe Pichia pastoris ( Pichia pastoris ), mammalian cells such as COS cells or Chinese hamster ovary (CHO) cells, insect cells, and plant cells such as Arabidopsis thaliana ( Arabidopsis thaliana ) and tobacco ( Nicotiana tabacumThe construct can be introduced into a host cell using any technique commonly known to those skilled in the art. For example, calcium phosphate precipitation, electroporation, heat shock, lipid transfection, microinjection, and virus-mediated nucleic acid transfer are common methods for introducing nucleic acids into host cells. Alternatively, naked DNA can be delivered directly into cells (see, for example, U.S. Patent Nos. 5,580,859 and 5,589,466).
[0047] Polymerase chain reaction (PCR) U.S. Patent Nos. 4,683,202, 4,683,195, 4,800,159, and 4,965,188 disclose conventional PCR techniques. PCR typically employs two oligonucleotide primers that bind to a selected nucleic acid template (e.g., DNA or RNA). These two oligonucleotide primers are typically a forward primer and a reverse primer. Primers useful in some embodiments include oligonucleotides capable of acting as the starting point for nucleic acid synthesis within the said HCV nucleic acid sequence (e.g., SEQ ID NO: 1, 2, and 3). Primers can be purified from restriction digests by conventional methods or can be synthesized. For maximum efficiency in amplification, the primers are preferably single-stranded, but the primers can be double-stranded. Double-stranded primers are first denatured, i.e., treated to separate the strands. One method of denaturing double-stranded nucleic acids is by heating.
[0048] If the template nucleic acid is double-stranded, the two strands need to be separated before it can be used as a template in PCR. Strand separation can be accomplished by any suitable denaturation method, including physical, chemical, or enzymatic methods. One method for separating nucleic acid strands involves heating the nucleic acid until it is significantly denatured (e.g., greater than 50%, 60%, 70%, 80%, 90%, or 95% denaturation). The heating conditions required to denature the template nucleic acid will depend, for example, the buffer salt concentration and the length and nucleotide composition of the nucleic acid being denatured, but are typically maintained for a period of time in the range of about 90°C to about 105°C, depending on characteristics of the reaction such as temperature and nucleic acid length. Denaturation is typically performed for about 30 seconds to 4 minutes (e.g., 1 minute to 2 minutes 30 seconds or 1.5 minutes).
[0049] If the double-stranded template nucleic acid is denatured by heat, the reaction mixture is allowed to cool to a temperature that promotes annealing of each primer with its target sequence. The annealing temperature is typically from about 35°C to about 65°C (e.g., from about 40°C to about 60°C; from about 45°C to about 50°C). The annealing time can be from about 10 seconds to about 1 minute (e.g., from about 20 seconds to about 50 seconds; from about 30 seconds to about 40 seconds). The reaction mixture is then adjusted to a temperature that promotes or optimizes polymerase activity, i.e., a temperature sufficient to allow extension from the annealed primer to occur to produce a product complementary to the template nucleic acid. The temperature should be sufficient to synthesize an extension product from each primer annealed to the nucleic acid template, but should not be high enough to denature the extension product from its complementary template (e.g., the extension temperature typically ranges from about 40°C to about 80°C (e.g., from about 50°C to about 70°C; from about 60°C). The extension time can be from about 10 seconds to about 5 minutes (e.g., from about 30 seconds to about 4 minutes; from about 1 minute to about 3 minutes; from about 1 minute 30 seconds to about 2 minutes).
[0050] The genomes of retroviruses or RNA viruses (e.g., HCV and other flaviviruses) contain ribonucleic acid, i.e., RNA. In such cases, the template RNA must first be transcribed into complementary DNA (cDNA) by the enzyme reverse transcriptase. Reverse transcriptase uses the RNA template and a short primer complementary to the 3' end of the RNA to guide the synthesis of the first-strand cDNA, which can then be used directly as a template for the polymerase chain reaction.
[0051] PCR assays can use target nucleic acids such as RNA or DNA (cDNA). The template nucleic acid does not need to be purified; it can be a minor fraction of a complex mixture, such as microbial target nucleic acids contained in human cells. This can be achieved using conventional techniques such as... Diagnostic Molecular Microbiology : Principles and Applications The types described in (Persing et al., 1993, American Society for Microbiology, Washington DC) refer to the extraction of microbial nucleic acid molecules from biological samples, such as those from viruses like HPV, WNV, HAV, HBV, HCV, and HIV. Nucleic acids can be obtained from any number of sources, such as plasmids or natural sources, including bacteria, yeast, viruses, organelles, or higher organisms such as plants or animals.
[0052] Oligonucleotide primers (e.g., for HCV, SEQ ID NO: 1-3) are combined with PCR reagents under reaction conditions that induce primer extension. For example, the chain extension reaction typically includes 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 15 mM MgCl2, 0.001% (w / v) gelatin, 0.5–1.0 µg of denatured template DNA, 50 pmol of each oligonucleotide primer, 2.5 U of Taq polymerase, and 10% DMSO. The reaction often contains 150–320 µM of each of dATP, dCTP, dTTP, dGTP, or one or more analogs thereof.
[0053] The newly synthesized strands form a double-stranded molecule that can be used in subsequent steps of the reaction. The strand separation, annealing, and extension steps can be repeated frequently as needed to produce the desired amount of amplified product corresponding to the target nucleic acid molecule. Limiting factors in the reaction are the amount of primers, thermostable enzymes, and nucleoside triphosphates present in the reaction. Preferably, the cycling steps (i.e., denaturation, annealing, and extension) are repeated at least once. For applications in detection, the number of cycling steps will depend, for example, on the nature of the sample. If the sample is a complex mixture of nucleic acids, more cycling steps will be needed to amplify a sufficient amount of the target sequence for detection. Typically, the cycling steps are repeated at least about 20 times, but can be repeated up to 40, 60, or even 100 times.
[0054] Fluorescence resonance energy transfer (FRET) FRET technology (see, for example, U.S. Patent Nos. 4,996,143, 5,565,322, 5,849,489, and 6,162,603) is based on the concept that when a donor fluorescent portion and a corresponding acceptor fluorescent portion are placed within a specific distance of each other, energy transfer occurs between the two fluorescent portions, which can be visualized or otherwise detected and / or quantified. When the donor is excited by light radiation of an appropriate wavelength, the donor typically transfers energy to the acceptor. The acceptor typically re-emits the transferred energy in the form of light radiation of a different wavelength. In some systems, non-fluorescent energy can be transferred between the donor and acceptor portions by including a biomolecule comprising a substantially non-fluorescent donor portion (see, for example, U.S. Patent No. 7,741,467).
[0055] In one example, an oligonucleotide probe may contain a donor fluorescent moiety (e.g., FAM) and a corresponding quencher (e.g., BlackHole Quenchers™ (BHQ) such as BHQ2), which may be fluorescent or non-fluorescent and dissipates the transferred energy in a form other than light. When the probe is intact, energy transfer typically occurs between the donor and acceptor moieties, such that fluorescence emission from the donor fluorescent moiety is quenched by the acceptor moiety. During the extension step of a polymerase chain reaction, the probe bound to the amplification product is cleaved by the 5' to 3' nuclease activity of, for example, Taq polymerase, such that fluorescence emission from the donor fluorescent moiety is no longer quenched. Exemplary probes for this purpose are described, for example, in U.S. Patent Nos. 5,210,015, 5,994,056, and 6,171,785. Commonly used donor-acceptor pairs include FAM-TAMRA pairs. Commonly used quenchers are DABCYL and TAMRA. Commonly used dark quenchers include BlackHole Quenchers™ (BHQ) (such as BHQ2) (Biosearch Technologies, Inc., Novato, Cal.), Iowa Black™ (Integrated DNATech., Inc., Coralville, Iowa), and BlackBerry™ Quencher 650 (BBQ-650) (Berry & Assoc., Dexter, Mich.).
[0056] In another example, two oligonucleotide probes (each containing a fluorescent moiety) hybridize with the amplification product at specific locations, determined by the complementarity of the oligonucleotide probes with the target nucleic acid sequence. After hybridization at the appropriate locations, the oligonucleotide probes generate a FRET signal. The hybridization temperature can be maintained at approximately 35°C to approximately 65°C for approximately 10 seconds to approximately 1 minute.
[0057] Fluorescence analysis can be performed using, for example, a photon-counting epifluorescence microscopy system (containing appropriate dichroic mirrors and filters for monitoring fluorescence emission within a specific range), a photon-counting photomultiplier system, or a fluorometer. Excitation can be performed using an argon-ion laser, a high-intensity mercury (Hg) arc lamp, a xenon lamp, a fiber optic light source, or other high-intensity light sources appropriately filtered for excitation within the desired range to induce energy transfer or allow direct detection of fluorophores.
[0058] As used herein with respect to donor and corresponding acceptor portions, "corresponding" means that the acceptor fluorescent portion or dark quencher has an absorption spectrum that overlaps with the emission spectrum of the donor fluorescent portion. The maximum wavelength of the emission spectrum of the acceptor fluorescent portion should be at least 100 nm greater than the maximum wavelength of the excitation spectrum of the donor fluorescent portion. Therefore, efficient nonradiative energy transfer can occur between them.
[0059] Fluorescent donors and corresponding acceptor moieties are typically selected for the following purposes: (a) high-efficiency Foerster energy transfer; (b) a large final Stokes shift (>100 nm); (c) an emission shift as far as possible into the red portion of the visible spectrum (>600 nm); and (d) an emission shift to a wavelength higher than that produced by excitation at the donor excitation wavelength for Raman water fluorescence. For example, a donor fluorescent moieties may be selected that have an excitation maximum near a laser line (e.g., helium-cadmium 442 nm or argon 488 nm), a high extinction coefficient, a high quantum yield, and good overlap of their fluorescence emission with the excitation spectrum of the corresponding acceptor fluorescent moieties. Similarly, a corresponding acceptor fluorescent moieties may be selected that have a high extinction coefficient, a high quantum yield, good overlap of their excitation with the emission of the donor fluorescent moieties, and emission in the red portion of the visible spectrum (>600 nm).
[0060] Representative donor fluorescent moieties that can be used with various acceptor fluorescent moieties in FRET technology include fluorescein, fluorescent yellow, β-phycoerythrin, 9-acridine isothiocyanate, fluorescent yellow VS, 4-acetamido-4'-isothiocyanoyl bis(stilbene-2,2'-disulfonic acid, 7-diethylamino-3-(4'-isothiocyanophenyl)-4-methylcoumarin, 1-pyrenebutyrate succinimide, and derivatives of 4-acetamido-4'-isothiocyanoyl bis(stilbene-2,2'-disulfonic acid). Depending on the donor fluorescent moiety used, representative acceptor fluorescent moieties include LC Red 640, LC Red 705, Cy5, Cy5.5, rhodamine B sulfonyl chloride, tetramethylrhodamine isothiocyanate, rhodamine x isothiocyanate, erythrosine isothiocyanate, fluorescein, diethylenetriaminepentaacetate, or other chelates of lanthanide ions (e.g., europium or terbium). Donor and acceptor fluorescent moieties can be obtained, for example, from Molecular Probes (Junction City, Oreg.) or Sigma Chemical Co. (St. Louis, Mo.).
[0061] The fluorescent portions of the donor and acceptor can be ligated to a suitable probe oligonucleotide via adapter arms. The length of each adapter arm is important because it affects the distance between the fluorescent portions of the donor and acceptor. The length of the adapter arm can be the distance from the nucleotide base to the fluorescent portion, expressed in angstroms (Å). Generally, adapter arms are about 10 Å to about 25 Å. Adapter arms can belong to the type described in International Patent Publication No. WO 84 / 03285. International Patent Publication No. WO 84 / 03285 also discloses methods for ligating adapter arms to specific nucleotide bases and for ligating fluorescent portions to adapter arms.
[0062] Recipient fluorescent moieties (such as LC Red 640) can be conjugated with oligonucleotides containing amino linkers (e.g., C6-aminoaminophosphite, available from ABI (Foster City, Calif.) or Glen Research (Sterling, VA)) to produce oligonucleotides such as LC Red 640-labeled oligonucleotides. Commonly used linkers for conjugating donor fluorescent moieties (such as fluorescein) to oligonucleotides include thiourea linkers (FITC-derived, e.g., fluorescein-CPG from Glen Research or ChemGene (Ashland, Mass.), amide linkers (fluorescein-NHS-ester-derived, such as CX-fluorescein-CPG from BioGenex (San Ramon, Calif.),) or 3'-amino-CPG, which requires conjugation of fluorescein-NHS-ester after oligonucleotide synthesis.
[0063] Detection of amplified target nucleic acid products (amplifiers) This invention provides a method for detecting and quantifying target nucleic acids (including microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV) in biological or non-biological samples. The provided method avoids problems of sample contamination, false negatives, and false positives. The method includes performing at least one cyclic step and a FRET detection step, the cyclic step comprising amplifying a portion of the target nucleic acid molecule from a sample (e.g., HPV, WNV, HAV, HBV, HCV, or HIV) using one or more target primer pairs and non-extension helper oligonucleotides. Preferably, multiple cyclic steps are performed in a thermal cycler. The method can be performed using target primers, non-extension helper oligonucleotides, and probes to detect the presence of target nucleic acids (e.g., HPV, WNV, HAV, HBV, HCV, or HIV). Detection of the target nucleic acid (by, for example, a probe) indicates the presence of the target nucleic acid (e.g., HPV, WNV, HAV, HBV, HCV, or HIV) in the sample.
[0064] As described in this article, amplification products can be detected using labeled hybridization probes utilizing FRET technology. One form of FRET utilizes TaqMan... ® The technology is used to detect the presence or absence of amplification products, and thus the presence or absence of HCV virus. TaqMan ® The technique utilizes a single-stranded hybridization probe labeled with, for example, a fluorescent dye (e.g., HEX) and a quencher (e.g., BHQ or BHQ-2, which may or may not be fluorescent). When the first fluorescent portion is excited with light of a suitable wavelength, the absorbed energy is transferred to a second fluorescent portion or a dark quencher according to the FRET principle. The second portion is typically a quencher molecule. During the annealing step of the PCR reaction, the labeled hybridization probe binds to the target DNA (i.e., the amplification product) and is degraded by the 5' to 3' nuclease activity of, for example, Taq polymerase during the subsequent extension phase. Thus, the fluorescent portion and the quencher portion become spatially separated from each other. As a result, fluorescence emission from the first fluorescent portion can be detected after excitation of the first fluorescent portion in the absence of a quencher. As an example, ABI PRISM... ® The 7700 sequence detection system (Applied Biosystems) uses TaqMan. ® The technology is suitable for performing the methods described herein for detecting the presence or absence of target nucleic acid / amplification products in the sample.
[0065] Molecular beacons bound to FRET can also be used to detect the presence of amplification products using real-time PCR methods. Molecular beacon technology uses hybridization probes labeled with a first fluorescent moiety and a second fluorescent moiety. The second fluorescent moiety is typically a quencher, and the fluorescent label is usually located at each end of the probe. Molecular beacon technology uses probe oligonucleotides with sequences that allow secondary structure formation (e.g., hairpins). Due to the formation of secondary structures within the probe, the two fluorescent moieties are spatially close when the probe is in solution. Upon hybridization with the target nucleic acid (i.e., the amplification product), the secondary structure of the probe is disrupted, and the fluorescent moieties become separated from each other, allowing the emission of the first fluorescent moiety to be detected upon excitation with light of an appropriate wavelength.
[0066] Another common form of FRET technology utilizes two hybridization probes. Each probe can be labeled with a different fluorescent moiety and is typically designed to hybridize closely to each other within the target DNA molecule (e.g., the amplification product). The donor fluorescent moiety (e.g., fluorescein) is fluorophored at 470 nm by LightCycler. ® The instrument is excited by a light source. During FRET, the luciferin transfers its energy to the fluorescent portion of the acceptor, such as the LightCycler. ®-Red 640 (LC Red 640) or LightCycler ® -Red705 (LC Red 705). The acceptor fluorescent portion then emits longer wavelength light, which is transmitted through a LightCycler. ® The instrument's optical detection system detects the fluorescence. Effective FRET occurs only when the fluorescent portions are in direct local proximity and when the emission spectrum of the donor fluorescent portion overlaps with the absorption spectrum of the acceptor fluorescent portion. The intensity of the emission signal can be correlated with the number of original target DNA molecules (e.g., the number of HCV genomes). If amplification of the target nucleic acid occurs and amplification products are generated, the hybridization step results in a detectable FRET signal based on the members of the probe pair.
[0067] Typically, the presence of FRET indicates the presence of the target nucleic acid in the sample, and the absence of FRET indicates the absence of the target nucleic acid in the sample. However, insufficient sample collection, transportation delays, inappropriate transportation conditions, or the application of certain collection swabs (calcium alginate or aluminum rods) can all affect the success and / or accuracy of test results.
[0068] Representative biological samples that can be used to practice the methods described include, but are not limited to, respiratory samples, urine, fecal samples, blood samples, plasma, skin swabs, nasal swabs, wound swabs, blood cultures, and skin and soft tissue infection materials. Methods for collecting and preserving biological samples are known to those skilled in the art. Biological samples can be processed (e.g., by nucleic acid extraction methods and / or kits known in the art) to release target nucleic acids (microbial target nucleic acids, such as HPV, WNV, HAV, HBV, HCV, and HIV), or in some cases, biological samples can be brought into direct contact with PCR reaction components and appropriate oligonucleotides.
[0069] Melting profile analysis is an additional step that can be included in the cycle profile. Melting profile analysis is based on the fact that DNA melts at a characteristic temperature known as the melting temperature (Tm), defined as the temperature at which half of the DNA duplex has separated into single strands. The melting temperature of DNA depends primarily on its nucleotide composition. Thus, DNA molecules rich in G and C nucleotides have a higher Tm than those rich in A and T nucleotides. The melting temperature of a probe can be determined by detecting the temperature at which the signal is lost. Similarly, the annealing temperature of a probe can be determined by detecting the temperature at which the signal is generated. The melting temperature of a target nucleic acid probe derived from the target nucleic acid amplification product can confirm the presence or absence of the target nucleic acid (e.g., microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV) in the sample.
[0070] During each thermal cycler run, control samples are also cycled. Positive control samples can be amplified using, for example, control primers and control probes to amplify the target nucleic acid control template (rather than the amplification product of the target gene). Positive control samples can also be amplified, for example, plasmid constructs containing the target nucleic acid molecule. Using the same primers and probes used to detect the intended target, such plasmid controls can be amplified internally (e.g., within the sample) or in a separate sample run alongside the patient's sample. Such controls indicate the success of the amplification, hybridization, and / or FRET reaction. Each thermal cycler run may also include a negative control, for example, one lacking the target template DNA. Negative controls can be used to measure contamination. This ensures that the system and reagents do not produce false positive signals. Therefore, control reactions can be readily determined, for example, the ability of primers to anneal and begin extension with sequence specificity, and the ability of probes to hybridize and induce FRET with sequence specificity.
[0071] In one embodiment, the method includes a step to avoid contamination. For example, enzymatic methods using uracil-DNA glycosylation enzymes to reduce or eliminate contamination between one thermal cycler run and the next are described in U.S. Patent Nos. 5,035,996, 5,683,896, and 5,945,313.
[0072] Conventional PCR methods combined with FRET technology can be used to practice the methods described. In one implementation, LightCycler is used. ® Instruments. The following patent application describes, as in LightCycler... ® The real-time PCR used in the technology: International Patent Publication Nos. WO 97 / 46707, WO 97 / 46714 and WO 97 / 46712.
[0073] LightCycler ® It can be run on a PC workstation and utilizes the Windows NT operating system. The machine acquires signals from the samples as the capillary is sequentially placed above the optical unit. The software can display the fluorescence signal in real time immediately after each measurement. The fluorescence acquisition time is 10-100 milliseconds (mssec). After each cycle step, the fluorescence quantification display relative to the number of cycles can be continuously updated for all samples. The generated data can be stored for further analysis.
[0074] As an alternative to FRET, double-stranded DNA binding dyes such as fluorescent DNA binding dyes (e.g., SYBR) can be used. ® Green or SYBR ®Gold (Molecular Probes) is used to detect amplification products. These fluorescent DNA-binding dyes emit a fluorescent signal upon excitation with light of an appropriate wavelength after interacting with double-stranded nucleic acids. Double-stranded DNA-binding dyes such as nucleic acid intercalation dyes can also be used. When using double-stranded DNA-binding dyes, melting curve analysis is typically performed to confirm the presence of amplification products.
[0075] Those skilled in the art will understand that other nucleic acid- or signal-amplification methods may also be used. Examples of such methods include, but are not limited to, branched DNA signal amplification, loop-mediated isothermal amplification (LAMP), nucleic acid sequence-based amplification (NASBA), self-persistent sequence replication (3SR), strand displacement amplification (SDA), or Smart Amplification Methods Version 2 (SMAP 2).
[0076] It should be understood that the embodiments of the present invention are not limited by the configuration of one or more commercially available instruments.
[0077] Products / Reagent Kits Embodiments of the present invention also provide articles or kits for detecting and quantifying target nucleic acids (e.g., microbial target nucleic acids, such as HPV, WNV, HAV, HBV, HCV, and HIV). Articles may include primers, non-extension auxiliary oligonucleotides, and probes for detecting gene targets (e.g., microbial target nucleic acids, such as HPV, WNV, HAV, HBV, HCV, and HIV), and suitable packaging materials. Representative primers and probes for detecting and quantifying target nucleic acids (e.g., microbial target nucleic acids, such as HPV, WNV, HAV, HBV, HCV, and HIV) are capable of hybridizing with the target nucleic acid molecule. Representative non-extension auxiliary oligonucleotides are capable of partially or completely annealing / hybridizing with the target nucleic acid molecule. In some cases, the non-extension auxiliary oligonucleotides and the (extension) primers are partially or completely identical to the target nucleic acid in partial annealing / hybridization. That is, the non-extension auxiliary oligonucleotides can be designed into the primer-binding region. Alternatively, the non-extension auxiliary oligonucleotides and the (extension) primers may not anneal / hybridize with the same portion of the target nucleic acid. Additionally, the kit may include appropriately packaged reagents and materials required for DNA immobilization, hybridization, detection, and quantification, such as solid supports, buffers, enzymes, and DNA standards. Methods for designing primers, non-extension auxiliary oligonucleotides, and probes are disclosed herein, and representative examples of primers, non-extension auxiliary oligonucleotides, and probes for amplifying and hybridizing target nucleic acid molecules are provided.
[0078] The article may also include one or more fluorescent portions for labeling probes, or alternatively, may label probes provided in the kit. For example, the article may include donor and / or acceptor fluorescent portions for labeling target nucleic acid probes (e.g., probes specific to microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV). Examples of suitable FRET donor fluorescent portions and corresponding acceptor fluorescent portions are provided above.
[0079] The product may also contain a packaging insert or label with instructions thereon on the use of primers, non-extension helper oligonucleotides, and probes to detect and quantify target nucleic acids (e.g., microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV) in a sample. The product may additionally include reagents for performing the methods disclosed herein (e.g., buffers, polymerases (e.g., DNA polymerase), nucleoside triphosphate monomers or other nucleoside monomers, cofactors, or contamination prevention agents). Such reagents may be specific to one of the commercially available instruments described herein.
[0080] Embodiments of the present invention also provide a set of primers, one or more non-elongation auxiliary oligonucleotides, and one or more detectable probes for detecting target nucleic acids (e.g., microbial target nucleic acids, such as HPV, WNV, HAV, HBV, HCV, and HIV) in a sample.
[0081] reaction mixture Embodiments of the present invention also provide reaction mixtures for amplifying, detecting, and quantifying target nucleic acids (e.g., microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV). The reaction mixture may include primers, non-extension auxiliary oligonucleotides, and probes for detecting gene targets (e.g., microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV), as well as suitable packaging materials. Representative primers, non-extension auxiliary oligonucleotides, and probes for detecting and quantifying target nucleic acids (e.g., microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV) are capable of hybridizing with the target nucleic acid molecule. Additionally, the kit may also include appropriately packaged reagents and materials, such as solid supports, buffers, enzymes, and DNA standards, required for DNA immobilization, hybridization, detection, and quantification. Methods for designing primers, non-extension auxiliary oligonucleotides, and probes are disclosed herein, and representative examples of primers, non-extension auxiliary oligonucleotides, and probes for amplifying and hybridizing with target nucleic acid molecules are provided.
[0082] The reaction mixture may also include one or more fluorescent moieties for labeling probes, or alternatively, probes supplied with the kit may be labeled. For example, the reaction mixture may include donor and / or acceptor fluorescent moieties for labeling target nucleic acid probes (e.g., probes specific to microbial target nucleic acids such as HPV, WNV, HAV, HBV, HCV, and HIV). Examples of suitable FRET donor fluorescent moieties and corresponding acceptor fluorescent moieties are provided above.
[0083] The reaction mixture may additionally include reagents for implementing the methods disclosed herein (e.g., buffers, polymerases (e.g., DNA polymerase), nucleoside triphosphate monomers or other nucleoside monomers, cofactors, or contamination prevention agents). Such reagents may be specifically designed for use with one of the commercially available instruments described herein.
[0084] Embodiments of the present invention also provide a set of primers, one or more non-elongation auxiliary oligonucleotides, and one or more detectable probes for detecting target nucleic acids (e.g., microbial target nucleic acids, such as HPV, WNV, HAV, HBV, HCV, and HIV) in a sample.
[0085] One embodiment of the present invention relates to a method for detecting and / or quantifying a target nucleic acid in a sample, the method comprising: (a) contacting the nucleic acid in the sample with an amplification reagent comprising: at least one enzyme having DNA polymerase activity; at least one nucleoside triphosphate monomer or other nucleoside monomer; at least one forward primer specific to the target nucleic acid, or at least one reverse primer specific to the target nucleic acid, or a combination thereof, for generating at least one amplicon; at least one non-extension helper oligonucleotide, wherein: (i) the non-extension helper oligonucleotide does not extend, (ii) the non-extension helper oligonucleotide anneals to a portion of the same portion of the primers as the target nucleic acid, and (iii) the non-extension helper oligonucleotide enhances the activity of at least one of the primers; and at least one detectable probe specific to the amplicon or at least one DNA-binding dye; (b) incubating the nucleic acid with the amplification reagent for a period of time under conditions sufficient to allow an amplification reaction to occur; and (c) detecting the amplicon with the at least one detectable probe or the at least one DNA-binding dye. In another embodiment, the target nucleic acid is a microbial nucleic acid (such as viral nucleic acid and / or bacterial nucleic acid). In some embodiments, the viral nucleic acid is the nucleic acid of human papillomavirus (HPV), West Nile virus (WNV), human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), or hepatitis C virus (HCV). In one relevant embodiment, the viral nucleic acid is the nucleic acid of hepatitis C virus (HCV) (including, for example, HCV genotype 5). In another embodiment, the at least one non-extending auxiliary oligonucleotide comprises a polyadenylated sequence at the 3' end of the at least one non-extending auxiliary oligonucleotide. In one relevant embodiment, the polyadenylated sequence has a length between 4 and 12 nucleotides, such as about 8 nucleotides. In another embodiment, the at least one non-extending auxiliary oligonucleotide comprises the sequence of SEQ ID NO:5 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence. In another embodiment, the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or their complementary sequences. In another embodiment, the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence; the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence; and the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence.
[0086] Another embodiment of the present invention relates to a method for detecting and / or quantifying HCV nucleic acid in a sample, the method comprising: (a) contacting the nucleic acid in the sample with an amplification reagent comprising: at least one enzyme having DNA polymerase activity; at least one nucleoside triphosphate monomer or other nucleoside monomer; at least one forward primer specific to the target nucleic acid, or at least one reverse primer specific to the target nucleic acid, or a combination thereof, for generating at least one amplicon; at least one non-extension auxiliary oligonucleotide, wherein: (i) the non-extension auxiliary oligonucleotide does not extend, (ii) the non-extension auxiliary oligonucleotide anneals to a portion of the same part of the target nucleic acid with at least one of the primers, and (iii) the non-extension auxiliary oligonucleotide enhances the activity of at least one of the primers; and at least one detectable probe specific to the amplicon or at least one DNA-binding dye; (b) incubating the nucleic acid with the amplification reagent for a period of time under conditions sufficient to allow an amplification reaction to occur; and (c) detecting the amplicon with the at least one detectable probe or the at least one DNA-binding dye. In another embodiment, the at least one non-elongating auxiliary oligonucleotide comprises a polyadenylated sequence at the 3' end of the at least one non-elongating auxiliary oligonucleotide. In another embodiment, the polyadenylated sequence has a length between 4 and 12 nucleotides, for example, about 8 nucleotides. In another embodiment, the HCV is HCV genotype 5. In another embodiment, the at least one non-elongating auxiliary oligonucleotide comprises the sequence of SEQ ID NO:5 or its complementary sequence. In one relevant embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence. In another embodiment, the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence. In another embodiment, the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence; the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and / or 3 or its complementary sequence; and the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence.
[0087] Another embodiment of the invention relates to a kit for amplifying and detecting and / or quantifying a target nucleic acid in a sample, the kit comprising an amplification reagent comprising: (a) an enzyme having DNA polymerase activity; (b) a nucleoside triphosphate monomer or other nucleoside monomer; (c) at least one forward primer or at least one reverse primer, or a combination thereof, specific to the target nucleic acid; (d) at least one non-extension auxiliary oligonucleotide, wherein: (i) the non-extension auxiliary oligonucleotide does not extend; (ii) the non-extension auxiliary oligonucleotide anneals to a portion of the same part of the target nucleic acid with at least one of the primers; and (iii) the non-extension auxiliary oligonucleotide enhances the activity of at least one of the primers; and (e) at least one detectable probe or DNA-binding dye of the target nucleic acid. In another embodiment, the target nucleic acid is a microbial nucleic acid (such as viral or bacterial nucleic acid). In one relevant embodiment, the viral nucleic acid is the nucleic acid of HPV, WNV, HIV, HAV, HBV, or HCV. In a more specific embodiment, the viral nucleic acid is the nucleic acid of HCV (including, for example, HCV genotype 5). In another embodiment, the at least one non-elongating auxiliary oligonucleotide comprises a polyadenylated sequence at the 3' end of the at least one non-elongating auxiliary oligonucleotide. In another embodiment, the polyadenylated sequence has a length between 4 and 12 nucleotides, for example, about 8 nucleotides. In another embodiment, the at least one non-elongating auxiliary oligonucleotide comprises the sequence of SEQ ID NO:5 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence. In another embodiment, the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence. In another embodiment, the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence; the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence; and the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence.
[0088] One relevant embodiment of the present invention relates to a kit for amplifying and detecting and / or quantifying HCV nucleic acid in a sample, the kit comprising an amplification reagent comprising: (a) an enzyme having DNA polymerase activity; (b) a nucleoside triphosphate monomer or other nucleoside monomer; (c) at least one forward primer or at least one reverse primer, or a combination thereof, specific to the target nucleic acid; (d) at least one non-extensional auxiliary oligonucleotide, wherein: (i) the non-extensional auxiliary oligonucleotide does not extend; (ii) the non-extensional auxiliary oligonucleotide anneals to a portion of the same part of the target nucleic acid with at least one of the primers; and (iii) the non-extensional auxiliary oligonucleotide enhances the activity of at least one of the primers; and (e) at least one detectable probe or DNA-binding dye of the target nucleic acid. In another embodiment, the at least one non-extensional auxiliary oligonucleotide comprises a polyadenylated sequence at the 3' end of the at least one non-extensional auxiliary oligonucleotide. In another embodiment, the polyadenylated sequence has a length between 4 and 12 nucleotides, for example, about 8 nucleotides. In another embodiment, the HCV is HCV genotype 5. In another embodiment, the at least one non-extension helper oligonucleotide comprises the sequence of SEQ ID NO:5 or its complementary sequence. In one related embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence. In another embodiment, the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence. In another embodiment, the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence; the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence; and the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence.
[0089] Another embodiment of the invention relates to a reaction mixture for efficiently amplifying and detecting and / or quantifying a target nucleic acid in a sample, the reaction mixture comprising an amplification reagent comprising: (a) a sample; (b) an enzyme containing DNA polymerase activity; (c) a nucleoside triphosphate monomer or other nucleoside monomer; (d) at least one forward primer or at least one reverse primer, or a combination thereof, specific to the target nucleic acid; (e) at least one non-extension auxiliary oligonucleotide, wherein: (i) the non-extension auxiliary oligonucleotide does not extend; (ii) the non-extension auxiliary oligonucleotide anneals a portion of the same part of the target nucleic acid to at least one of the primers; and (iii) the non-extension auxiliary oligonucleotide enhances the activity of at least one of the primers; and (f) at least one detectable probe or DNA-binding dye of the target nucleic acid. In another embodiment, the target nucleic acid is a microbial nucleic acid. In another embodiment, the microbial nucleic acid is a viral nucleic acid. In another embodiment, the microbial nucleic acid is a bacterial nucleic acid. In another embodiment, the viral nucleic acid is the nucleic acid of HPV, WNV, HIV, HAV, HBV, or HCV. In one specific embodiment, the viral nucleic acid is the nucleic acid of HCV (including, for example, HCV genotype 5). In another embodiment, the at least one non-extending auxiliary oligonucleotide comprises a polyadenylated sequence at the 3' end of the at least one non-extending auxiliary oligonucleotide. In another embodiment, the polyadenylated sequence has a length between 4 and 12 nucleotides, for example, about 8 nucleotides. In another embodiment, the at least one non-extending auxiliary oligonucleotide comprises the sequence of SEQ ID NO:5 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence. In another embodiment, the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence. In another embodiment, the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence; the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence; and the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence.
[0090] One relevant embodiment of the present invention relates to a reaction mixture for efficiently amplifying and detecting and / or quantifying HCV nucleic acid in a sample, the reaction mixture comprising an amplification reagent comprising: (a) a sample; (b) an enzyme comprising DNA polymerase activity; (c) a nucleoside triphosphate monomer or other nucleoside monomer; (d) at least one forward primer or at least one reverse primer, or a combination thereof, specific to the target nucleic acid; (e) at least one non-extensional auxiliary oligonucleotide, wherein: (i) the non-extensional auxiliary oligonucleotide does not extend; (ii) the non-extensional auxiliary oligonucleotide anneals to a portion of the same part of the target nucleic acid with at least one of the primers; and (iii) the non-extensional auxiliary oligonucleotide enhances the activity of at least one of the primers; and (f) at least one detectable probe or DNA-binding dye of the target nucleic acid. In another embodiment, the at least one non-extensional auxiliary oligonucleotide comprises a polyadenylated sequence at the 3' end of the at least one non-extensional auxiliary oligonucleotide. In another embodiment, the polyadenylated sequence has a length between 4 and 12 nucleotides, for example, about 8 nucleotides. In one embodiment, the HCV is HCV genotype 5. In another embodiment, the at least one non-extension auxiliary oligonucleotide comprises the sequence of SEQ ID NO:5 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence. In another embodiment, the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence. In another embodiment, the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence. In another embodiment, the at least one forward primer comprises the sequence of SEQ ID NO:1 or its complementary sequence; the at least one reverse primer comprises a sequence selected from SEQ ID NO:2 and 3 or its complementary sequence; and the at least one probe comprises the sequence of SEQ ID NO:4 or its complementary sequence.
[0091] The embodiments of the present invention will be further described in the following examples. Example
[0092] The following embodiments and accompanying drawings are provided to aid in understanding the subject matter, the true scope of which is set forth in the appended claims. It should be understood that modifications can be made to the described procedure without departing from the spirit of the invention.
[0093] Example 1: Detection of HCV by real-time PCR RNA samples for real-time PCR assays were extracted from plasma samples of HCV-positive individuals. Reagents used included the cobas® 6800 / 8800 Universal PCR Master Mix, following protocols and conditions used with the cobas® 6800 / 8800, and TaqMan® detection and quantification technology was employed. In 50 μl PCR reactions, the final concentrations were as follows: forward and reverse primers in the range of 0.2–0.5 μM; non-extension auxiliary oligonucleotides at 0.20 μM; and probe at 0.12 μM. Concentrations of forward and reverse primers and non-extension auxiliary oligonucleotides in the range of 0.10–0.50 μM are believed to be effective.
[0094] To confirm the role of the non-extension helper oligonucleotide, real-time PCR assays were performed in duplicate using HCV-positive human plasma samples under the following two experimental conditions: (1) real-time PCR with only primer pairs and probes (i.e., without the non-extension helper oligonucleotide); and (2) real-time PCR with primer pairs, the non-extension helper oligonucleotide, and the probe. The HCV genotype 5-specific oligonucleotides used for the real-time PCR assays were SEQ ID NO:1 (for the forward primer), SEQ ID NO:2 and 3 (for the reverse primer), SEQ ID NO:5 (for the non-extension helper oligonucleotide), and SEQ ID NO:4 (for the probe). The non-extension helper oligonucleotide (SEQ ID NO:5) is a 53-base-pair unlabeled oligonucleotide with a polyadenylated tail at its 3' end and is designed into a reverse primer that binds to the core region of the HCV genome.
[0095] For these HCV-positive human plasma samples, Figure 2 The predicted secondary structure of the HCV target region in the presence of the aforementioned non-elongation auxiliary oligonucleotides was depicted, showing a ΔG of -107.2 kcal / mol (CLC GenomicsWorkbench 6, Qiagen), and the results are displayed in [the table / data]. Figure 1 The figure shows the real-time PCR growth curve. (As shown in...) Figure 1 As observed, the PCR reaction is more efficient in the presence of non-extension helper oligonucleotides than in their absence.
[0096] These results confirm that the PCR reaction is more robust and efficient in the presence of the aforementioned non-extension auxiliary oligonucleotides. In other words, the accumulation of PCR products is increased in the presence of the aforementioned non-extension auxiliary oligonucleotides compared to their absence.
[0097] Example 2: Detection of HCV genotype 5 by real-time PCR As in Example 1, RNA samples for real-time PCR assays were extracted from HCV-positive human plasma samples, different from those used in Example 1. The reagents used, as in Example 1, included the cobas® 6800 / 8800 Universal PCR Master Mix, using the protocols and conditions employed with the cobas® 6800 / 8800, and TaqMan® detection and quantification technology. In a 50 μl PCR reaction, the final concentrations were as follows: forward and reverse primers in the range of 0.2–0.5 μM; non-extension auxiliary oligonucleotides at 0.20 μM; and probe at 0.12 μM. It is believed that concentrations of forward and reverse primers and non-extension auxiliary oligonucleotides in the range of 0.10–0.50 μM will be effective.
[0098] To confirm the role of the non-extension helper oligonucleotide, real-time PCR assays were performed in duplicate using HCV-positive human plasma samples (different from those used in Example 1) under the following two experimental conditions: (1) real-time PCR with only primer pairs and probes (i.e., without the non-extension helper oligonucleotide); and (2) real-time PCR with primer pairs, the non-extension helper oligonucleotide, and the probe. The HCV genotype 5-specific oligonucleotides used for the real-time PCR assays were SEQ ID NO:1 (for the forward primer), SEQ ID NO:2 and 3 (for the reverse primer), SEQ ID NO:5 (for the non-extension helper oligonucleotide), and SEQ ID NO:4 (for the probe). As in Example 1, the non-extension helper oligonucleotide (SEQ ID NO:5) was a 53-base-pair unlabeled oligonucleotide with a polyadenylated tail at its 3' end and was designed into a reverse primer that binds to the core region of the HCV genome.
[0099] For this specific HCV-positive human plasma sample, Figure 4 The predicted secondary structure of the HCV target region in the presence of the aforementioned non-elongation auxiliary oligonucleotides is depicted, showing a ΔG of -98.6 kcal / mol, and the results are displayed in [the table / image / data]. Figure 3 The figure shows the real-time PCR growth curve. (As shown in...) Figure 3 As observed, the PCR reaction is more efficient in the presence of non-extension helper oligonucleotides than in their absence.
[0100] These results confirm that the PCR reaction is more robust and efficient in the presence of the aforementioned non-extension auxiliary oligonucleotides. In other words, the accumulation of PCR products is increased in the presence of the aforementioned non-extension auxiliary oligonucleotides compared to their absence.
[0101] In summary, these two examples demonstrate that, in different samples, the non-elongation auxiliary oligonucleotides of the present invention exhibit a reduction in the Gibbs free energy of the secondary structure of the target nucleic acid, which promotes the approach of the target nucleic acid to the primer. This leads to improved amplification efficiency. Therefore, the non-elongation auxiliary oligonucleotides increase the sensitivity of amplification assays.
[0102] Although the foregoing invention has been described in considerable detail for clarity and understanding, those skilled in the art will recognize upon reading this invention that various changes in form and detail may be made without departing from the true scope of the invention. For example, all the techniques and devices described above can be used in different combinations. sequence list <110> F. Hoffmann-La Roche AG <120> Auxiliary oligonucleotides used to improve the efficiency of nucleic acid amplification and detection / quantification. <130> P33737-WO-KOE <150> 62 / 370,049 <151> 2016-08-02 <160> 5 <170> PatentIn version 3.5 <210> 1 <211> 18 <212> DNA <213> Artificial sequence <220> <223> forward primer <220> <221> Modified bases <222> (18)..(18) <223> tert-butylbenzyl-dC <400> 1 tgggcagggt ggttgctc 18 <210> 2 <211> 25 <212> DNA <213> Artificial sequence <220> <223> reverse primer <220> <221> Modified bases <222> (25)..(25) <223> tert-butylbenzyl-dA <400> 2 gttgcatagt ttaccccgtc ctcaa 25 <210> 3 <211> 25 <212> DNA <213> Artificial sequence <220> <223> reverse primer <220> <221> Modified bases <222> (25)..(25) <223> tert-butylbenzyl-dA <400> 3 gttgcatagt ttatcccgtc ctcaa 25 <210> 4 <211> 25 <212> DNA <213> Artificial sequence <220> <223> Primers <400> 4 atcccgctcg taggcggccc cgttg 25 <210> 5 <211> 53 <212> DNA <213> Artificial sequence <220> <223> Non-elongation auxiliary oligonucleotides <400> 5 gttgcatagt ttatcccgtc ttcaagaacc ttcacaccgt gtgcgaaaaa aaa 53
Claims
1. Use of non-elongation auxiliary oligonucleotides in the preparation of a kit for performing a method for detecting and / or quantifying hepatitis C virus (HCV) genotype 5 target nucleic acid in a sample by real-time polymerase chain reaction, said method comprising: (a) Contacting the nucleic acid in the sample with an amplification reagent, the amplification reagent comprising: At least one enzyme containing DNA polymerase activity; At least a nucleoside triphosphate monomer or other nucleoside monomer; Forward and reverse primers specific to the target nucleic acid, used to generate at least one amplicon, wherein the forward primer consists of the sequence of SEQ ID NO:1 and the reverse primer consists of sequences selected from SEQ ID NO:2 and 3; The non-elongation auxiliary oligonucleotide, composed of the sequence of SEQ ID NO:5, thereby enhancing the overall efficiency of the amplification reaction; and A detectable probe specific to the amplicon, wherein the detectable probe consists of the sequence of SEQ ID NO:4 or its complementary sequence; (b) Incubate the nucleic acid together with the amplification reagent for a period of time under conditions sufficient to allow the amplification reaction to occur; and (c) Detect the amplicon using the detectable probe.
2. A kit for amplifying and detecting and / or quantifying hepatitis C virus (HCV) genotype 5 target nucleic acid in a sample, the kit comprising amplification reagents, wherein the amplification reagents for performing a real-time polymerase chain reaction comprise: (a) An enzyme containing DNA polymerase activity; (b) Nucleoside triphosphate monomers or other nucleoside monomers; (c) Forward and reverse primers specific to the target nucleic acid, wherein the forward primer consists of the sequence of SEQ ID NO:1 and the reverse primer consists of the sequence selected from SEQ ID NO:2 and 3; (d) A non-elongation auxiliary oligonucleotide consisting of the sequence of SEQ ID NO:5, wherein the non-elongation auxiliary oligonucleotide enhances the overall efficiency of the amplification reaction; and (e) The detectable probe of the target nucleic acid, wherein the detectable probe consists of the sequence of SEQ ID NO:4 or its complementary sequence.
3. A reaction mixture for efficiently amplifying and detecting and / or quantifying hepatitis C virus (HCV) genotype 5 target nucleic acid in a sample in a real-time polymerase chain reaction, said reaction mixture comprising an amplification reagent comprising: (a) Sample; (b) Enzymes containing DNA polymerase activity; (c) Nucleoside triphosphate monomers or other nucleoside monomers; (d) Forward and reverse primers specific to the target nucleic acid, wherein the forward primer consists of the sequence of SEQ ID NO:1 and the reverse primer consists of the sequence selected from SEQ ID NO:2 and 3; (e) A non-elongation auxiliary oligonucleotide comprising the sequence of SEQ ID NO:5, wherein the non-elongation auxiliary oligonucleotide enhances the overall efficiency of the amplification reaction; and (f) A detectable probe for the target nucleic acid, wherein the detectable probe consists of the sequence of SEQ ID NO:4 or its complementary sequence.
Citation Information
Patent Citations
Process for improving efficiency of DNA amplification reaction
US20040110182A1
Method for Preventing High Molecular Weight Products During Amplification
US20140113279A1
Process for amplifying, detecting, and / or-cloning nucleic acid sequences
US4683195A
Process for amplifying nucleic acid sequences
US4683202A
Process for amplifying, detecting, and / or cloning nucleic acid sequences
US4800159A
